PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Reproductive Control Agents”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 649 records · Page 36Linked to original sources
PubMed1983

A comparison of Norinyl and Brevicon in three sites in Sri Lanka.

A set of 3 four-cell randomized, blind clinical trials was carried out in Sri Lanka to evaluate the impact of vitamin supplements and different oral contraceptive formulations. This paper concentrates on the comparisons of oral contraceptives. There seems to be no important difference between Norinyl, a standard-dose oral contraceptive, and Brevicon of a lower estrogen dosage--in either continuation or side effects. Continuation at one site was higher among Norinyl users, but several factors led us to the belief that this difference was due to differences in field worker performance rather than to the pharmacological properties of the drugs. Some differences in side effects were observable along predictable lines; breakthrough bleeding was more common among Brevicon users than Norinyl users, and most other side effects were more frequent among Norinyl users, although these latter differences were quite small, and there were several exceptions.

Adolescent↗
PubMed1987

Metabolic effects of combined oral contraceptive preparations.

Fasting intermediary metabolite concentrations were measured in comparable groups of women either in the follicular or luteal phase of the menstrual cycle or taking low-dose estrogen combined oral contraceptive preparations. Blood total ketone bodies concentrations were significantly elevated in oral contraceptive users (p less than 0.05 v follicular and luteal groups) whilst blood alanine levels were lower (p less than 0.01 v follicular).

3-Hydroxybutyric Acid↗
PubMed1985

Effects of short-term treatment with a combined oestrogen-progestin oral contraceptive on biliary lipids and cholesterol saturation index in young women.

The effect of daily ingestion for 7 days of ethinyloestradiol (30 micrograms) plus DL-norgestrel [0.5 mg] (Eugynon-30) on the lipid composition of duodenal bile in 8 healthy young women was investigated from the fifth day after onset of menstrual bleeding. This treatment did not significantly affect the concentrations of cholesterol, phospholipid and total bile acids expressed as mmol/l, nor the mean molar percentage of phospholipid. However, the treatment caused a significant increase in the mean molar percentage of cholesterol which was accompanied by a significant decrease in the mean molar percentage of total bile acids. The cholesterol saturation index of the bile of 7 subjects was elevated after treatment while both serum cholesterol and testosterone were significantly reduced. The results show that administration to healthy young women, not previously exposed to oral contraceptives, with a low oestrogen-progestin preparation for only 7 days produces a more lithogenic bile, accompanied by a decrease in serum cholesterol and plasma testosterone concentrations.

Adult↗
PubMed1982

The effects of two years of mestranol treatment on carbohydrate metabolism.

Twenty-nine menstrual age women who had a hysterectomy and oophorectomy were treated cyclically with 80 micrograms of mestranol per day for 2 yr. Their carbohydrate metabolism was evaluated prospectively by doing a 3 hr oral glucose tolerance test after a 100 g glucose load and measuring both blood glucose and plasma insulin levels. The tests were performed before drug treatment and after 2 yr of drug use. Those women that had a "normal" predrug test had some carbohydrate metabolism changes at the 2 yr test with significant elevations of the fasting, 1 and 2 hr blood glucose values, and also significant elevations of the 2 and 3 hr plasma insulin values. Those women with a "borderline abnormal" predrug test had no significant change in either parameter of carbohydrate metabolism however a trend toward similar changes was noted.

Adult↗
PubMed1985

Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.

Four groups of eight or nine normal cycling volunteers with regular menstrual cycles had daily blood sampling during two pretreatment, two treatment, and two posttreatment cycles. Intranasal doses of 100, 200, and 300 micrograms of (D-Ser[TBU]6-des-Gly-NH210) luteinizing hormone-releasing hormone (LH-RH) ethylamide were administered every 12 hours and compared with a 400-micrograms dose given every 24 hours during two periods of 21 days followed by a drug-free interval of 7 days. Five milligrams of medroxyprogesterone acetate was taken orally on days 17 to 21. Serum luteinizing hormone was elevated during the first 2 weeks of treatment, and serum follicle-stimulating hormone was increased only during the first 2 days of treatment. At 100 to 300 micrograms/12 hours serum estradiol was stimulated up to preovulatory levels, whereas at 400 micrograms/24 hours most values were in the early follicular phase range. Ovarian ultrasonography revealed the transient development of preovulatory-like follicles in 8 of 12 studied cycles. Serum progesterone values were less than 2 ng/ml in 57.3%, between 2 and 5 ng/ml in 27.9%, and greater than 5 ng/ml in 14.7%. Withdrawal bleeding occurred during the pause in 97% of treatment cycles. Nine of 13 breakthrough bleedings happened in the groups given 100-micrograms and 300-micrograms/12 hours. Recovery cycles showed slightly prolonged follicular phases with normal luteal phases. No changes were observed in routine laboratory measurements. In conclusion, intermittent administration of appropriate LH-RH agonist dosing in combination with a progestogen would effectively block ovulation while preserving adequate cyclic estradiol secretion and could be an alternative contraceptive approach.

Administration, Intranasal↗
PubMed1986

Sustained intrauterine release of levonorgestrel over five years.

Two models of levonorgestrel-releasing intrauterine devices were studied. Model A was designed to deliver 20 micrograms/day, and model B was designed to deliver 30 micrograms/day. Plasma concentrations of levonorgestrel were determined in blood samples taken from women who used the levonorgestrel-releasing intrauterine devices (IUDs) and who participated in a clinical trial for more than 5 years. During clinical studies IUDs have been removed for various reasons between 8 and 40 months after insertion. The rate of release of levonorgestrel from the IUDs was calculated by determining the remaining amount of levonorgestrel. Plasma concentrations of levonorgestrel ranged between a mean +/- standard deviation (SD) concentration of 166 +/- 75 pg/ml and 131 +/- 32 pg/ml for the first 18 months of use and between 101 +/- 37 pg/ml and 74 +/- 15 pg/ml at 24 and 60 months after insertion of the IUD. The plasma concentrations from 24 months through 60 months were significantly lower than concentrations measured during initial months of IUD use, but not between the two devices. There was a strong correlation between the time of use and the amount of levonorgestrel lost from the IUDs. The calculated mean daily release of levonorgestrel was 17.6 micrograms for model A and 22.2 micrograms for model B. This gives a calculated lifetime of more than 6 years for a levonorgestrel-releasing IUD.

Clinical Trials as Topic↗
PubMed1983

Case-control study of rheumatoid arthritis and prior use of oral contraceptives.

This study was designed to determine whether oestrogens in oral contraceptives and other drugs have a protective effect against development of rheumatoid arthritis. The medical records of 229 women with rheumatoid arthritis and 458 individually matched controls identified through the comprehensive records system for the population of Rochester, Minnesota, were examined for current and prior use of oestrogens. No association was found between rheumatoid arthritis and the use of oral contraceptives, or the use of oestrogens for menopause-related or postmenopausal symptoms.

Adolescent↗
PubMed1983

Normophasic preparation containing progestogen desogestrel and ethinylestradiol.

A Finnish multicenter study was carried out on 157 healthy fertile volunteers (2157 cycles) to evaluate an oral normophasic contraceptive preparation comprising 7 tablets of 0.050 ethinyl estradiol followed by 15 tablets of 0.050 mg ethinyl estradiol + 0.125 mg desogestrel. Bleeding patterns, side effects, liver function, and dropouts were recorded, as well as the development of the endometrium. No pregnancies occurred. Irregular bleeding (spotting and breakthrough bleeding) occurred in 12% of the 1st treatment cycle and in only 4% after 1 year's treatment. The most common side effects were nausea and headache. 17 women dropped out because of subjective side effects after 12 treatment cycles. No changes of any clinical importance were seen in mean body weight or liver function tests. Most of the endometrial biopsies showed a secretory pattern with mild hypoplasia. No hyperplastic or malignant changes were seen.

Anxiety↗
PubMed1992

Selected aspects of polycystic ovarian disease.

Although there is general agreement about the polycystic ovary as an anatomic entity, a classic description of an associated syndrome remains elusive. This lack of definition, however, has not impeded clinical investigation. This article focuses on the diagnosis, pathogenesis, hypotheses, and treatment of polycystic ovarian disease.

Adrenal Cortex Hormones↗
PubMed1987

[Contragestion].

Explore the source record for details and available documents.

Contraceptives, Postcoital↗
PubMed1985

[Microval].

Explore the source record for details and available documents.

Contraceptives, Oral, Combined↗